Stryker (SYK) Stock Forecast & Price Target

$295.38 +4.51 (+1.55%)

Closing price 05/5/2026 03:59 PM Eastern

Extended Trading

$293.32 -2.06 (-0.70%)

As of 05/5/2026 07:54 PM Eastern

Compare

Stryker - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 22 Analyst Ratings

Sell
0

Hold
6

Buy
16

Based on 22 Wall Street analysts who have issued ratings for Stryker in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 22 analysts, 6 have given a hold rating, and 16 have given a buy rating for SYK.

Consensus Price Target

$395.48
33.88% Upside

According to the 22 analysts' twelve-month price targets for Stryker, the average price target is $395.48. The highest price target for SYK is $465.00, while the lowest price target for SYK is $315.00. The average price target represents a forecasted upside of 33.88% from the current price of $295.39.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for SYK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Stryker and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SYK Analyst Ratings Over Time

Type	Current Forecast 5/6/25 to 5/6/26	1 Month Ago 4/6/25 to 4/6/26	3 Months Ago 2/5/25 to 2/5/26	1 Year Ago 5/6/24 to 5/6/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	16 Buy rating(s)	14 Buy rating(s)	12 Buy rating(s)	15 Buy rating(s)
Hold	6 Hold rating(s)	5 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$395.48	$427.50	$426.94	$427.05
Forecasted Upside	33.88% Upside	28.61% Upside	17.73% Upside	13.04% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

SYK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SYK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Stryker Stock vs. The Competition

Type	Stryker	Medical Companies	S&P 500
Consensus Rating Score	2.73	2.30	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	33.88% Upside	938.17% Upside	14.75% Upside
News Sentiment Rating	Neutral News See Recent SYK News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
5/4/2026	Weiss Ratings Not Rated		Downgrade	Hold (C+) ➝ Hold (C)
5/4/2026	Truist Financial 3 of 5 stars	Richard Newitter 2 of 5 stars	Reiterated Rating	Hold	$380.00 ➝ $330.00	+13.11%
5/4/2026	Barclays 3 of 5 stars	Matt Miksic 2 of 5 stars	Lower Target	Overweight	$469.00 ➝ $394.00	+33.36%
5/1/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Roman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral	$361.00	+22.19%
5/1/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$410.00	+35.16%
5/1/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$385.00	+27.40%
5/1/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$355.00	+17.48%
5/1/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$315.00	+1.65%
5/1/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kyle Rose Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$435.00 ➝ $400.00	+35.39%
5/1/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$445.00 ➝ $400.00	+33.29%
Get the Latest News and Ratings for SYK and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Stryker and its competitors with MarketBeat's FREE daily newsletter.
5/1/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$456.00 ➝ $418.00	+35.99%
5/1/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ryan Zimmerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$397.00 ➝ $379.00	+20.46%
5/1/2026	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Matson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$454.00 ➝ $418.00	+32.85%
4/13/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Kratky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$410.00	+20.83%
4/7/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joanne Wuensch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$420.00 ➝ $385.00	+15.69%
3/17/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Antalffy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$400.00 ➝ $380.00	+7.81%
3/5/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
3/4/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Taylor Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$465.00	+21.57%
1/27/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight
1/26/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold	$387.00	+8.35%
1/6/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$418.00	+19.86%
12/19/2025	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Turkaly Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$440.00	+24.63%
11/14/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$435.00	+16.64%
9/18/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$420.00	+11.54%
5/2/2025	Roth Mkm Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jason Wittes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$405.00 ➝ $456.00	+20.75%
2/3/2025	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Toung Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$450.00	+17.62%
1/29/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$400.00 ➝ $440.00	+11.41%
12/2/2024	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight	$370.00 ➝ $445.00	+13.48%
9/10/2024	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$405.00	+11.64%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 03:14 AM ET.

Should I Buy Stryker Stock? SYK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, May 1, 2026. Please send any questions or comments about these Stryker pros and cons to contact@marketbeat.com.

Stryker
Bull Case

Here are some ways that investors could benefit from investing in Stryker Co.:

The company has shown resilience by maintaining its full-year guidance despite recent operational disruptions, forecasting organic net sales growth of 8%–9.5% and adjusted EPS of $14.90–$15.10.
Stryker Co. has a strong return on equity of 24.41%, indicating effective management and profitability relative to shareholder equity.
The current stock price is around $314, which may present a buying opportunity for investors looking for growth in the medical technology sector.
Recent acquisitions, such as the agreement to acquire Amplitude Vascular Systems, are expected to enhance Stryker's offerings in the cardiovascular market, potentially driving future revenue growth.
There is ongoing momentum in the orthopedics segment, with record installations of the latest Mako robotic systems, which could lead to increased market share and sales in this competitive field.

Stryker
Bear Case

Investors should be bearish about investing in Stryker Co. for these reasons:

The company recently reported earnings that missed analysts' expectations by $0.38 EPS, which may raise concerns about its short-term performance and market confidence.
Operational challenges due to a cyber incident have caused delays in shipments and revenue recognition, which could impact sales and profitability in the near term.
Organic sales growth was muted at 2.4%, with specific segments showing lower growth rates, indicating potential weaknesses in market demand.
Increased costs from tariffs and higher interest expenses have negatively affected profit margins, which could pressure future earnings.
Despite a strong market position, the stock has seen fluctuations, with a recent decline of about 0.2%, suggesting volatility that may concern risk-averse investors.

SYK Forecast - Frequently Asked Questions

: According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Stryker is $395.48, with a high forecast of $465.00 and a low forecast of $315.00.
: 22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last twelve months. There are currently 6 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SYK shares.
: According to analysts, Stryker's stock has a predicted upside of 33.88% based on their 12-month stock forecasts.
: Over the previous 90 days, Stryker's stock had 1 downgrade by analysts.
: Stryker has been rated by research analysts at Barclays, BTIG Research, Canaccord Genuity Group, Citigroup, Deutsche Bank Aktiengesellschaft, Evercore, Jefferies Financial Group, JPMorgan Chase & Co., Leerink Partners, Needham & Company LLC, Robert W. Baird, Sanford C. Bernstein, The Goldman Sachs Group, Truist Financial, UBS Group, Weiss Ratings, Wells Fargo & Company, and William Blair in the past 90 days.
: Analysts like Stryker more than other "medical" companies. The consensus rating for Stryker is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how SYK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Stryker Recommendations

This page (NYSE:SYK) was last updated on 5/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stryker (SYK) Stock Forecast & Price Target

Stryker - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

SYK Analyst Ratings Over Time

SYK Analyst Recommendations By Month

SYK Price Targets by Month

Stryker Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Stryker Stock? SYK Pros and Cons Explained

Stryker
Bull Case

Stryker
Bear Case

SYK Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Stryker Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Stryker (SYK) Stock Forecast & Price Target

Stryker - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

SYK Analyst Ratings Over Time

SYK Analyst Recommendations By Month

SYK Price Targets by Month

Stryker Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Stryker Stock? SYK Pros and Cons Explained

Stryker Bull Case

Stryker Bear Case

SYK Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Stryker Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Stryker
Bull Case

Stryker
Bear Case